Goldman Sachs
MREO

Goldman Sachs’s Mereo BioPharma MREO Stock Holding History

Goldman Sachs’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.1K Buy
+85,180
New +$25.5K ﹤0.01% 6454
2026
Q1 		– Sell
-28,026
Closed -$11.7K – 6808
2025
Q4 		$11.7K Sell
28,026
-2,335,998
-99% -$4.45M ﹤0.01% 6360
2025
Q3 		$4.87M Sell
2,364,024
-726,044
-23% -$1.34M ﹤0.01% 3671
2025
Q2 		$8.37M Buy
3,090,068
+964,148
+45% +$2.33M ﹤0.01% 2922
2025
Q1 		$4.78M Buy
2,125,920
+6,068
+0.3% +$17.2K ﹤0.01% 3400
2024
Q4 		$7.42M Buy
2,119,852
+111,471
+6% +$438K ﹤0.01% 3066
2024
Q3 		$8.25M Sell
2,008,381
-499,132
-20% -$2.06M ﹤0.01% 2910
2024
Q2 		$9.03M Buy
2,507,513
+263,699
+12% +$854K ﹤0.01% 2591
2024
Q1 		$7.4M Buy
2,243,814
+220,142
+11% +$745K ﹤0.01% 2756
2023
Q4 		$4.67M Hold
2,023,672
– – ﹤0.01% 3215
2023
Q3 		$2.61M Buy
2,023,672
+41,266
+2% +$54.8K ﹤0.01% 3551
2023
Q2 		$2.62M Sell
1,982,406
-280,379
-12% -$325K ﹤0.01% 3665
2023
Q1 		$1.6M Sell
2,262,785
-31,981
-1% -$28.8K ﹤0.01% 4034
2022
Q4 		$1.72M Buy
2,294,766
+1,585,640
+224% +$1.3M ﹤0.01% 4051
2022
Q3 		$611K Sell
709,126
-8,329
-1% -$10.2K ﹤0.01% 4843
2022
Q2 		$804K Buy
717,455
+2,270
+0.3% +$1.76K ﹤0.01% 4774
2022
Q1 		$801K Buy
715,185
+2,822
+0.4% +$3.65K ﹤0.01% 5000
2021
Q4 		$1.14M Buy
+712,363
New +$1.42M ﹤0.01% 4733

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Goldman Sachs's MREO Position: Q2 2026 in Review

Goldman Sachs opened a new position in Mereo BioPharma (MREO) in Q2 2026: 85,180 shares worth $27.1K. The stake represents ﹤0.01% of the portfolio and ranks #6454 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in MREO as recently as Q4 2025.

Goldman Sachs first reported a position in MREO in Q4 2021 and has held it in 18 quarters since. The position peaked at $9.03M in Q2 2024. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

  • Goldman Sachs held 85,180 shares of Mereo BioPharma worth $27.1K as of Q2 2026.
  • Mereo BioPharma was a new Goldman Sachs position in Q2 2026.
  • Mereo BioPharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6454 holding.
  • Goldman Sachs first reported a position in Mereo BioPharma in Q4 2021 and has held it in 18 quarters since.
  • Goldman Sachs's Mereo BioPharma position peaked at $9.03M in Q2 2024.
  • 61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.